Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Acetic acid Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhanced Recovery at Cesarean Birth to Improve Postoperative Outcomes and Reduce Postoperative Length of Stay

NCT02956616
View directory record Official record
Conditions
Cesarean Section
Interventions
ketorolac, Chewing Gum, Enhanced Recovery Protocol
Drug · Other · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Exploratory Investigation of a Supplement to Promote Cognitive Health Benefits

NCT05523115
View directory record Official record
Conditions
Anxiety, Stress, Memory Deficits, Cortisol Overproduction
Interventions
Heights Smart Supplement
Dietary Supplement
Lead sponsor
Heights
Industry
Eligibility
21 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 1 Interventional

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2

NCT03332355
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
PAC-1 Compound
Drug
Lead sponsor
Vanquish Oncology, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional

An Outpatient Study Investigating Non-prescription Treatments for COVID-19

NCT04621149
View directory record Official record
Conditions
COVID-19
Interventions
chlorine dioxide, zinc acetate, Famotidine, placebo, lactoferrin, green tea extract
Other · Dietary Supplement · Drug
Lead sponsor
Profact, Inc.
Other
Eligibility
20 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies

NCT01290380
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
ASA404, DMXAA, DXAA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin B6 Supplementation and Mood States in College Women Taking Oral Contraceptives

NCT04070391
View directory record Official record
Conditions
Depression
Interventions
vitamin B6, control
Dietary Supplement · Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Sep 9, 2026, 11:15 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

NCT04190550
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Interventions
Cytarabine, Idarubicin Hydrochloride, Navtemadlin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

NCT00532311
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and stable statin therapy, Stable statin therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional

Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation

NCT01999764
View directory record Official record
Conditions
Impaired Dark Adaptation
Interventions
QLT091001, Placebo
Drug · Other
Lead sponsor
QLT Inc.
Industry
Eligibility
60 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Artesia, California • Santa Barbara, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Sep 9, 2026, 11:15 AM EDT
Enrolling by invitation Phase 2 Interventional

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

NCT02402660
View directory record Official record
Conditions
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions
ALK-001, Placebo
Drug
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

NCT01723020
View directory record Official record
Conditions
Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Glioblastoma, Multiple Myeloma
Interventions
AMG 232
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Santa Monica, California • Norwalk, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 1 Interventional

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

NCT03107780
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Navtemadlin, Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

NCT03369002
View directory record Official record
Conditions
Hepatic Impairment
Interventions
seladelpar
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

NCT04024813
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Seladelpar, Placebo to match Seladelpar
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 9, 2026, 11:15 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

NCT07810946
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions
Sodium Acetate, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 1Phase 2 Interventional

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

NCT00561197
View directory record Official record
Conditions
Locally Advanced Esophageal or GE Junction Cancer
Interventions
AT-101
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional

Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00390403
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
R-(-)-gossypol acetic acid, temozolomide, gene expression analysis, mutation analysis, protein expression analysis, laboratory biomarker analysis, pharmacological study, adjuvant therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Sep 9, 2026, 11:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of EED on Zn Absorption and Retention in Children From a Standard Dose

NCT02760095
View directory record Official record
Conditions
Environmental Enteric Dysfunction, Zinc Deficiency, Vitamin A Deficiency
Interventions
3 mg zinc sulfate supplement, 0.5 mg of 13C10-retinyl-acetate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Months to 24 Months
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 30, 2019 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Vitamin A Absorption From Fortified Bouillon

NCT06438562
View directory record Official record
Conditions
Healthy Volunteers, Vitamin A
Interventions
Unfortified bouillon plus vitamin A in oil, Bouillon fortified with vitamin A #1 plus unfortified oil, Bouillon fortified with vitamin A #2 plus unfortified oil
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia

NCT00487994
View directory record Official record
Conditions
Dyslipidemia
Interventions
Lapaquistat acetate, Lapaquistat acetate and atorvastatin, Atorvastatin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

NCT00440388
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
AT-101, Rituximab
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial

NCT02972424
View directory record Official record
Conditions
Osteoporotic Fractures
Interventions
Teriparatide Prefilled Syringe, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
65 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects

NCT00627120
View directory record Official record
Conditions
Healthy
Interventions
VGX-1027
Drug
Lead sponsor
VGX Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2009 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

NCT00666666
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
Interventions
AT-101, Bicalutamide, LHRH agent
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 9, 2026, 11:15 AM EDT